Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB308 · 1 trial · 10 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Q3W Cohorts | EXPERIMENTAL | Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies. |
| Dose Escalation Q4W Cohorts | EXPERIMENTAL | Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies. |
| Dose Escalation Q6W Cohort | EXPERIMENTAL | Selected dose of AB308 in combination with zimberelimab will be given every 6 weeks in participants with advanced malignancies. |
| Dose Expansion Cohort 1 | EXPERIMENTAL | AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC. |
| Dose Expansion Cohort 2 | EXPERIMENTAL | AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma. |
| Dose Expansion Cohort 3 | EXPERIMENTAL | AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer. |
| Dose Expansion Cohort 4 | EXPERIMENTAL | AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer. |
| Dose Expansion Cohort 5 | EXPERIMENTAL | AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies. |
| Name | Type | Description |
|---|---|---|
| AB308 | DRUG | Administered intravenously (IV) as specified in the treatment arm |
| Zimberelimab | DRUG | Administered IV as specified in the treatment arm |
Inclusion Criteria: * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for particip...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AB308 is an investigational small molecule being developed by Arcus Biosciences, Inc. for the treatment of advanced solid tumors and other advanced malignancies. It is a Phase 1 oncology candidate and has not been approved by the FDA. It was studied in combination with another agent, AB122, in a completed early-stage clinical trial.
AB308 targets TIGIT, a protein receptor. TIGIT is an immune checkpoint expressed on T cells and natural killer cells, and targeting it is intended to support anti-tumor immune activity. AB308 is a small molecule directed at this protein target, which distinguishes it from antibody-based TIGIT agents.
AB308 is being developed by Arcus Biosciences, Inc., a biopharmaceutical company that trades under the ticker RCUS. Arcus is the sponsor of the clinical program evaluating AB308 in advanced malignancies, including the completed Phase 1 study conducted in the United States, Poland, and Spain.
AB308 is in Phase 1 clinical development. It is an investigational agent and is not FDA approved. The Phase 1 trial evaluating AB308 has been completed, and no active trials of AB308 are currently listed. The program enrolled 94 participants in its completed study.
AB308 has been evaluated in the Phase 1 trial NCT04772989, titled A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies. That trial is completed and enrolled 94 participants across the United States, Poland, and Spain. It was a controlled study without randomization or double blinding.
AB308 was studied in advanced solid tumors and other advanced malignancies, including non-small cell lung cancer, melanoma, cervical cancer, gastric cancer, gastroesophageal junction adenocarcinoma, esophageal cancer, diffuse large B cell lymphoma, non-Hodgkin lymphoma, and multiple myeloma. The Phase 1 trial NCT04772989 enrolled adults 18 years and older.